Alzheimer’s treatment via the microbiome.

This month (Feb 2021) there as a major article Structural and Functional Dysbiosis of Fecal Microbiota in Chinese Patients With Alzheimer’s Disease released. I have updated my list of bacteria (with links to source studies),

This post is for caregivers that are interest in low risk treatment that theoretically have a high probability of success and low cost.

Short Summary of Approach

The microbiome produces some 4000+ different chemicals. For many conditions, especially “untreatable”, it appears that imbalances in these chemical mixtures result in cells, including brain cells, malfunctioning.

Some drugs help — and often those drugs were seen to alter the microbiome, correcting some of these shifts. The stupid question is this, if we know the bacteria that are involved — then why not starve or feed to put it into better balance.

IMHO It works! In my 50’s I had a sudden onset of cognitive issues, including memory. A SPECT scan was read as Early Onset Alzheimer’s. I also had another diagnosis. That other diagnosis has a bacteria shift pattern reported in 1998 in Australia. Making changes to alter that pattern caused the cognitive issues to fade and disappear.


You need to have a microbiome sample (done by taking a little bit of a stool and sending it to a lab). Then the data need to be upload to the free citizen science site, Microbiome Prescription. Not all labs are supported (i.e. they do not make their data available in a suitable format); those that are supported are listed here (with discount codes).

Once the data is uploaded, there are two Quick Suggestions links that generates suggestions using Fuzzy Logic Artificial Intelligence techniques.

There is a demo logic that show all of the features…. BiomeSight Example Login

There are a lot of tools there, depending on you skill sets and devotion to seeking improvement.

There is a YouTube Channel showing how to use this site and discussion of issues.

2 thoughts on “Alzheimer’s treatment via the microbiome.

  1. The more scientists have learned about the community of benign bacteria inside our bodies, known as the microbiome, the more effort they have put into recruiting it in the fight against disease. What’s more, scientists occasionally discover that treatments long thought to work completely independently of our native microbes also relieve symptoms by interacting with them. New IRP research into the most commonly used medication for type 2 diabetes has led to just such a revelation by demonstrating that its benefits stem in part from its ability to kill off a particular species of bacteria in the human digestive tract. Patients with type 2 diabetes  cannot adequately control the amount of sugar, or glucose, in their blood. The resulting chronically high blood sugar can eventually cause numerous problems, including cardiovascular disease and nerve damage. A drug called metformin is typically the first prescribed to lower blood sugar in these patients. Most studies of metformin suggest that it works by altering the way the liver produces glucose, but the question is far from settled.

  2. I m interested in studying this for two reasons: the first reason is that these patients are becoming more common as the use of ICI therapy increases. We need appropriate therapies to treat these patients and get them well enough to continue their oncology treatment. The second reason is from an IBD perspective, this provides a unique opportunity to study the development of inflammation in the gut. As an IBD specialist, most patients I see already have the disease and sometimes they may have had it for months, even years. Whenever we ve studied the basic science behind gut immunology, we re looking at an environment where the gut and associated biome has already changed due to the inflammation. OB: Studying patients with immunotherapy-colitis affords us an opportunity to study samples before and after the use of ICI. Only some of the patients undergoing therapy will develop colitis. We can use patients that don t develop colitis as a control group to study the differences in the microbiome and the immune system that associates with colitis. The NanoString project provides us with an additional opportunity to look at the colitis in more detail and improve our understanding of what is going on in the gut.

Comments are closed.